EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheumatoid arthritis and C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• IDACIO (ADALIMUMAB-AACF)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 05/08/2026